1) "counseled by several industry veterans" What industry

New Post Public Reply Private Reply Replies (3) Message Board
gobears1985 longboardsurfer90210 #21252
Quote:
1) "counseled by several industry veterans" What industry veterans? He needs counseling?
Do you expect him to name names? I also don't think you understand the word counsel in this context.

2) "chief among them being patience and faith." Part of the counseling he received was an industry veteran telling him to be patient and that it takes time? Really?
I'm not getting your point. I think there are a lot of examples of patience being important and development taking time

3) "current team." You mean, whats left of the current team?
Just because a few people have left doesn't mean there is nobody left.

4) "while also delivering significant value to a healthcare system stretched to its financial capacity.” Yeah, that’s what he is concerned about.
Non-issue. Not worth commenting on. You're just nit-picking here.

5) "near-term liquidity events." Ahh- the ever so elusive near term event.
Ever so elusive until it happens, then it's not elusive anymore. It only takes one.

6) "the Board of Directors has given management the mandate to accelerate our partnering initiatives in order to acquire the resources necessary to move the rest of the portfolio forward. " Oh, so the reason we don’t have any partners for ANY OF OUR ASSETS is because management never forced us to consider them?
He said they have given the mandate to accelerate the partnering initiatives, not that they haven't ever considered it before. Also, they have more assets to partner now than they used to have.

7) "while preserving and/or transferring value to our shareholders along the way." This statement needs zero comment.
You're not providing the context of the quote. He's talking about shareholder value increasing if they partner an asset, which is obvious. So yes, there is no comment needed.

8) " transact on either ESS or Eltoprazine in order to further refine the Company’s profile into a regenerative medicine company (ESS + MANF + Phenoguard) or a neurology company (Eltoprazine + MANF + Phenoguard)" In other words, we have no idea who we are or what we are about. And what the hell does “transact on” mean?
Sell or partner. Read it carefully. If we sell ESS, we keep Elto. If we sell Elto, we keep ESS. It's not about not knowing who we are. It's about our options after we sell one of the assets involved.

9) "could provide a pipeline for a very valuable standalone public company." There is the elusive “could provide” but hasn’t yet, but keep holding your breath.
If it was already provided, this blog would not have been necessary because we'd all be rich. Just because it hasn't happened, doesn't mean it can't happen.

10) "conditions in the market for our common shares rapidly deteriorated in the third quarter." -It just gets better. Conditions in the market didn’t deteriorate the value, getting into bed with toxic financiers did. This was the one I was REALLY hoping to not hear. The CEO is directly responsible for the deterioration of the share price….PERIOD! Nice try Gerald, by passing the buck.
Discounting the market conditions and placing 100% of the blame on the CEO is ludicrous. I'm not saying the market conditions were 100% of the problem either, but no one person or situation is 100% responsible.

11) "value appreciation of our common stock could potentially occur." – Again, been hearing that for the last 3 years.
Just because it hasn't happened doesn't mean it can't happen

12) "As we evaluate potential business development opportunities." What potential business development opportunities do they have to evaluate? Been hearing this one forever. Must be attached to those ever elusive NDA’s.
Good question on your part. If you really expect specific details, you don't know how things work.

13) "we are working behind the scenes to understand." – In other words, “ we don’t know what’s going on.” That’s a great place to be after destroying all of the long term shareholders value.
Stop taking quotes out of context. He's referring to their course of action regarding the ODD pathway for Elto. It's likely they don't know yet, which is entirely reasonable.

14) "begin evaluating Phase 3 development plans for adult ADHD as well as Phase 2 development plans for Alzheimer’s aggression." - “Begin evaluating”? Means nothing.
You have to plan before you can start a trial.

15) "Given the recent uptick in interest in Alzheimer’s therapies" – Recent? The interest in Alzheimers therapies is not “recent”.
I think he's referring to AVXL here.

16) "we are especially excited about the potential to develop Eltoprazine in this area" – Ahhhhh. The overly used “especially excited”.
Nit-picking again. Do you want him to say they are not excited?

17) "made good progress on the commercial launch plan for MSPrecise® at a meeting we held in Dallas, TX." Ahhhh, the overly used “made good progress” statement. Meeting with who? Who wants MS Precise? We have had it for how long?
You're not going to find this out until it's sold.

18) " continuing to evaluate the next set of studies to further enhance LymPro’s value - Ahhhh, the “continuing to evaluate” statement. I thought this thing was going to be generating revenue so that we would not have to dilute. Besides, “a reverse split may not even be necessary.”
Go back to the Lympro blog by Dr. Trzepacz and refresh your memory

19) "and will forego the option agreement with Georgetown University." – Hence, “we have no more money to continue with our option agreement.” I thought this was necessary to strengthen the diagnostics suite and increase the accuracy of the Lympro test?
They are studying Lympro in conjuction with PET. I don't think they want to put money into advancing G'town if they are going to sell Lympro off in the near future.

20) "that we recently completely enrollment." - A fricken spelling error? Does not anyone re-read these things before they post them?
This time, I agree with you. That bugs me.

21) "we believe we have sufficient critical mass." – And again the “we believe”. Obviously the market does not share your belief.
The market doesn't believe until it does believe. It doesn't mean it won't happen

22) "are now focused on the CLIA launch plans for these products. – I thought this was going to happen ages ago. “Now focused”?
Plans change.

23) "We remain on track to transact on the diagnostics division"- Really? Remain on track? That’s a subjective term. For when? 2030?
STOP QUOTING PORTIONS OF SENTENCES. Literally, the next words were "in the fourth quarter." Geez.

24) "as a key time to potentially make public announcements of definitive agreements." – This is the best. “Potentially make” and “definitive agreements” used in the same sentence.
He can't say exactly when announcements will come if he doesn't know when agreements will be final. At least he gives a ballpark estimate of a date and time.

25) "we believe the sheer strength of our portfolio will allow the Company to overcome the challenges we face." – Yeah, its doing such a good job so far. The only challenge we need to overcome is to figure out how to get someone in there that knows what they are doing.
GC's not going anywhere so you might as well stop thinking about it.

26) "we believe we have a strong execution plan, with achievable milestones" – “Believe”? How about “know”? Also, heard this many times in the past.
Semantics. Nit-picking again.

27)"We believe the support of our shareholders at this time in our corporate history is paramount." – This one takes the trophy! And we should support you because? Based on this piece of crap blog? Based on all of things you have claimed that never happened? Your stellar communication? It’s as if he does not even realize that many of us are down 90% +. He has given us zero reason to support his, what I now consider, delusional visions.
Then don't support them and sell your shares. Easy solution.

28) "working with our team" – what team? Who is left?
I already responded to this one earlier. See #3.

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AST SpaceMobile Faces Class Action Over Misstatements

Updated Category News Views 3

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Continue Reading
AI and Storytelling Make Waves in Science Education

Updated Category News Views 5

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

Continue Reading
Endurance Energy's Modular Tech Revs Up Southeast Asia

Updated Category News Views 3

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Continue Reading
Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Updated Category News Views 3

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

Continue Reading
Cut Winter Heating Costs with Townsend's Rebate Help

Updated Category News Views 5

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

Continue Reading
Geron Corp Faces Fiduciary Duty Investigation

Updated Category News Views 7

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

Continue Reading
HONA Faces Legal Heat: Investor Lawsuit Over Losses

Updated Category News Views 6

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Continue Reading
China Southern Airlines Marks 70th Anniversary in NYC

Updated Category News Views 3

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Continue Reading
CVS Health Under Fire: Fiduciary Duty Breach?

Updated Category News Views 2

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Continue Reading
Jackson Wang's Fantasy IP Hits Hong Kong Stage

Updated Category News Views 5

A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...

Continue Reading

Top 5 Most Recently Viewed Articles

Mitsubishi Electric Showcases Innovations at Aerospace Expo 2024

Updated Category News Views 312

Mitsubishi Electric Corporation made waves back in 2024 with its ambitious plans for the Japan International Aerospace Exhibition (JA2024). The event took place at Tokyo Big Sight, a venue buzzing with energy, where Mitsubishi unveiled its latest advancements in aerospace technology. This wasn't just a show-and-tell; they were out to prove how their innovations could...

Continue Reading
CBRE Group Acquires Industrious to Enhance Workplace Services

Updated Category News Views 560

CBRE Group Announces Acquisition of Industrious CBRE Group, Inc. (NYSE: CBRE) has revealed an exciting new chapter as it embarks on a significant acquisition of Industrious National Management Company, LLC, a leader in flexible workplace solutions. This move promises to revolutionize how buildings operate, enhancing the utility and appeal of physical spaces. Alongside...

Continue Reading
Simply Allulose Market Growth: Insights and Innovations Ahead

Updated Category News Views 113

Simply Allulose Market Overview The global Simply Allulose market is witnessing transformative growth, currently valued at US$ 276.41 million, with expectations to reach US$ 892.50 million by 2033. This significant growth trajectory, marked by a compound annual growth rate (CAGR) of 13.91%, showcases the rising popularity of low-calorie sweeteners. Innovative Developments...

Continue Reading
Troubling Times for Intel: Stock Continues to Plummet

Updated Category News Views 74

Intel's Stock Performance Report Intel's shares have been on a downward trajectory, with recent reports highlighting an additional decline due to persistent challenges in the semiconductor sector. The situation has been exacerbated by disappointing results from Broadcom's evaluation of Intel's advanced 18A manufacturing process, leading to a decrease in confidence...

Continue Reading
Empowering Canadians in Retirement: Seminar Series by Nancy Lee

Updated Category News Views 106

Nancy Lee Launches Retirement Seminar Series for Canadians In the current financial landscape, retiring successfully presents a unique set of challenges for Canadians. Faced with market fluctuations, rising healthcare expenses, and evolving tax regulations, many individuals are concerned about their financial stability in retirement. A recent report highlighted that a...

Continue Reading